Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I/II Open Label, Safety And Preliminary Efficacy Study of MRx0518 In Combination With Pembrolizumab In Patients With Advanced Malignancies Who Have Progressed On PD-1/PD-L1 Inhibitors

Next Previous
Trial Profile

A Phase I/II Open Label, Safety And Preliminary Efficacy Study of MRx0518 In Combination With Pembrolizumab In Patients With Advanced Malignancies Who Have Progressed On PD-1/PD-L1 Inhibitors

Status: Discontinued
Phase of Trial: Phase I/II

Latest Information Update: 05 Jun 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs CJRB 102 (Primary) ; Pembrolizumab (Primary)
  • Indications Advanced breast cancer; Bladder cancer; Head and neck cancer; Malignant melanoma; Non-small cell lung cancer; Renal cell carcinoma; Solid tumours; Squamous cell cancer; Triple negative breast cancer
  • Focus Adverse reactions; First in man; Proof of concept; Therapeutic Use
  • Sponsors 4D Pharma PLC

Most Recent Events

  • 30 May 2023 Status changed from active, no longer recruiting to discontinued.
  • 05 Jul 2022 Status changed from recruiting to active, no longer recruiting.
  • 31 Mar 2022 According to a 4D pharma media release, the company will provide update on next steps in Phase I/II study of MRx0518 and Keytruda in the Renal Cell Carcinoma (RCC) group in 2022.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top